---
title: "美國 FDA：多家制藥企業召回超過 58 萬瓶被致癌物污染的降壓藥"
description: "美國 FDA 宣佈，多家制藥企業召回超過 58 萬瓶被致癌物污染的降壓藥鹽酸哌唑嗪。此次召回由新澤西州的梯瓦製藥和美源健康服務公司自願啓動，因部分藥物可能含有亞硝胺類雜質，屬於潛在致癌物。FDA 將此事件列為 “二級風險事件”。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263774335.md"
published_at: "2025-10-31T14:43:41.000Z"
---

# 美國 FDA：多家制藥企業召回超過 58 萬瓶被致癌物污染的降壓藥

> 美國 FDA 宣佈，多家制藥企業召回超過 58 萬瓶被致癌物污染的降壓藥鹽酸哌唑嗪。此次召回由新澤西州的梯瓦製藥和美源健康服務公司自願啓動，因部分藥物可能含有亞硝胺類雜質，屬於潛在致癌物。FDA 將此事件列為 “二級風險事件”。

當地時間 10 月 31 日，美國食品藥品監督管理局表示，多家制藥企業召回超過 58 萬瓶被致癌物污染的降壓藥鹽酸哌唑嗪。FDA 稱，新澤西州的梯瓦製藥美國公司及美源健康服務公司已於本月初啓動自願全國召回。該藥用於擴張血管、降低血壓，也常被用於治療創傷後應激障礙引發的噩夢與睡眠問題。FDA 在公告中指出，部分批次藥物可能含有亞硝胺類雜質，這是一種在藥品生產或儲存過程中形成的潛在致癌化合物。監管機構已將此次召回列為 “二級風險事件”。

### Related Stocks

- [TEVA.US - 梯瓦制藥](https://longbridge.com/zh-HK/quote/TEVA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug | Teva Pharmaceutical Industries Ltd. has entered a funding agreement with Royalty Pharma worth up to $500 million to adva | [Link](https://longbridge.com/zh-HK/news/272304721.md) |
| Judge Denies Teva Bid To Pause Paragard Copper Contraceptive Device Lawsuit Trial | A federal judge has denied Teva Pharmaceutical Industries' request to delay the first trial related to its Paragard IUD, | [Link](https://longbridge.com/zh-HK/news/272440521.md) |
| Options trades to play for a short squeeze in Hims & Hers as the pain piles up | Hims & Hers has faced significant challenges, including a lawsuit from Novo Nordisk and a 48% drop in stock value over t | [Link](https://longbridge.com/zh-HK/news/275789087.md) |
| Teva Canada Signs Agreement with Novartis to Commercialize Mayzent for MS Patients | Teva Canada Limited has signed a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. for Ma | [Link](https://longbridge.com/zh-HK/news/274518158.md) |
| Teva posts FY non-GAAP net income of USD 3.41 billion, up 19% | Teva Pharmaceutical Industries Ltd. reported a FY non-GAAP net income of USD 3.41 billion, a 19% increase, with a non-GA | [Link](https://longbridge.com/zh-HK/news/274668783.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。